Healthcare >> CEO Interviews >> May 29, 2000
RAMESH C. PANDEY, MSc, PhD, DDG, Chairman, President, Chief Executive
Officer and Founder of Xechem, Inc. and XetaPharm, Inc., and President
and CEO of Xechem International, has had a distinguished career in the
biomedical sciences spanning over 35 years. He has served numerous
universities, government agencies and pharmaceutical companies
worldwide, including: The National Cancer Institute; LyphoMed, Inc.; The
University of Illinois; Rutgers, The State University of NJ; The
National Chemical Laboratory; Abbott Laboratories; and others. He has
made over 90 presentations at national and international conferences and
seminars, has authored (or co-authored) 85 peer-reviewed scientific
papers, and contributed to several books treating chemistry or
biochemistry topics of major importance. He also holds several US and
international patents for biotechnology analysis and rare drug
production process, including paclitaxel, a plant product used for the
treatment of ovarian, breast and small cell lung cancers and AIDs-
related Kaposi's Sarcoma. Dr. Pandey is a member of the editorial board
of The Journal of Antibiotics and of several professional societies,
including the American Chemical Society, American Association for Cancer
Research, American Society of Pharmacognosy, American Society of
Microbiology, Industrial Microbiology, Indian Science Congress and New
York Academy of Sciences. Profile
to set the stage for readers?
Dr. Pandey: Xechem is a bio-pharmaceutical company dealing with
antibiotics and anticancer
